Even though ASXL1 mutations are known to be independently associated with poor prognosis in MDS and CMML (NCCN Guidelines for MDS, https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf accessed on 3 Feburary 2024), DTA mutations are not specific to MDS. Here, ASXL1 is linked to myelodysplastic syndrome.